Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2009

Open Access 01-12-2009 | Case report

Visual hallucinations associated with varenicline: a case report

Authors: B Mahendri Raidoo, Eric C Kutscher

Published in: Journal of Medical Case Reports | Issue 1/2009

Login to get access

Abstract

Introduction

Varenicline is widely used for smoking cessation. It has shown efficacy over placebo and bupropion in manufacturer-sponsored trials. Those with mental illness were excluded from these trials. There are case reports of exacerbation of mental illness and development of psychiatric symptoms with varenicline use.

Case presentation

A 61-year-old male Caucasian being treated for post-traumatic stress disorder, depression not otherwise specified and alcohol dependence, was prescribed varenicline while he was in a post-traumatic stress disorder/alcohol dual diagnosis treatment program. He developed visual hallucinations, which became worse with titration of the medication. These symptoms resolved upon discontinuation of varenicline.

Conclusion

Patients with mental illness have a higher incidence of nicotine dependence, and attempts should be made for smoking cessation. Varenicline has not been widely tested in this population. There are reports of exacerbation of mental illness, and probable causation of psychiatric symptoms in the mentally ill. Providers should be aware of this possibility and advise their patients appropriately.
Literature
1.
go back to reference Foulds J: The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. 2006, 60: 571-576. 10.1111/j.1368-5031.2006.00955.x.CrossRefPubMed Foulds J: The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. 2006, 60: 571-576. 10.1111/j.1368-5031.2006.00955.x.CrossRefPubMed
2.
go back to reference Chantix TM: Pfizer Inc, 10.1176/appi.ajp.2007.07020326. Chantix TM: Pfizer Inc, 10.1176/appi.ajp.2007.07020326.
3.
go back to reference Freedman R: Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007, 164: 1269-10.1176/appi.ajp.2007.07020326.CrossRefPubMed Freedman R: Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007, 164: 1269-10.1176/appi.ajp.2007.07020326.CrossRefPubMed
4.
go back to reference Kohen I, Kremen N: Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007, 164: 1270-10.1176/appi.ajp.2007.07010173.CrossRef Kohen I, Kremen N: Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007, 164: 1270-10.1176/appi.ajp.2007.07010173.CrossRef
5.
go back to reference Morstad A, Kutscher E, Kennedy W, Carnahan R: Hypomania with agitation associated with varenicline use in bipolar II disorder. Ann Pharmacother. 2008, 42: 288-10.1345/aph.1K511.CrossRefPubMed Morstad A, Kutscher E, Kennedy W, Carnahan R: Hypomania with agitation associated with varenicline use in bipolar II disorder. Ann Pharmacother. 2008, 42: 288-10.1345/aph.1K511.CrossRefPubMed
6.
go back to reference Jorenby DE, Taylor Hays J, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, for the Varenicline Phase 3 Study Group: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation a randomized controlled trial. JAMA. 2006, 296: 56-63. 10.1001/jama.296.1.56.CrossRefPubMed Jorenby DE, Taylor Hays J, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, for the Varenicline Phase 3 Study Group: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation a randomized controlled trial. JAMA. 2006, 296: 56-63. 10.1001/jama.296.1.56.CrossRefPubMed
7.
8.
go back to reference Moore TJ, Cohen MR, Furberg CD: Strong safety signal seen for new varenicline risks: The Institute for Safe Medication Practices. Moore TJ, Cohen MR, Furberg CD: Strong safety signal seen for new varenicline risks: The Institute for Safe Medication Practices.
9.
go back to reference Stapleton JA, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcilffe M, Sutherland G: Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement and an evaluation in those with mental illness. Addiction. 2007, 103: 146-154. 10.1111/j.1360-0443.2007.02083.x.CrossRefPubMed Stapleton JA, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcilffe M, Sutherland G: Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement and an evaluation in those with mental illness. Addiction. 2007, 103: 146-154. 10.1111/j.1360-0443.2007.02083.x.CrossRefPubMed
10.
go back to reference American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 2000, American Psychiatric Association, 265-267. 4 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 2000, American Psychiatric Association, 265-267. 4
11.
go back to reference Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30: 239-245. 10.1038/clpt.1981.154.CrossRefPubMed Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30: 239-245. 10.1038/clpt.1981.154.CrossRefPubMed
12.
go back to reference Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. 2007, CD006103- Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. 2007, CD006103-
13.
go back to reference Etter JF: Cytisine for smoking cessation. A literature review and a meta-analysis. Arch Intern Med. 2006, 166: 1553-1559. 10.1001/archinte.166.15.1553.CrossRefPubMed Etter JF: Cytisine for smoking cessation. A literature review and a meta-analysis. Arch Intern Med. 2006, 166: 1553-1559. 10.1001/archinte.166.15.1553.CrossRefPubMed
14.
go back to reference Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, for the Varenicline Phase 3 Study Group: Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006, 296: 47-55. 10.1001/jama.296.1.47.CrossRefPubMed Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, for the Varenicline Phase 3 Study Group: Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006, 296: 47-55. 10.1001/jama.296.1.47.CrossRefPubMed
15.
go back to reference Oncken C, Gonzales D, Nides M, Rennard SI, Watsky EJ, Billing CB, Anziano R, Reeves KR, for the Varenicline Study Group: Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006, 166: 1571-1577. 10.1001/archinte.166.15.1571.CrossRefPubMed Oncken C, Gonzales D, Nides M, Rennard SI, Watsky EJ, Billing CB, Anziano R, Reeves KR, for the Varenicline Study Group: Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006, 166: 1571-1577. 10.1001/archinte.166.15.1571.CrossRefPubMed
16.
go back to reference Fatemi SH: Varenicline efficacy and tolerability in a subject with schizophrenia. Schizophr Res. 2008, 103: 328-329. 10.1016/j.schres.2008.05.002.CrossRefPubMed Fatemi SH: Varenicline efficacy and tolerability in a subject with schizophrenia. Schizophr Res. 2008, 103: 328-329. 10.1016/j.schres.2008.05.002.CrossRefPubMed
17.
Metadata
Title
Visual hallucinations associated with varenicline: a case report
Authors
B Mahendri Raidoo
Eric C Kutscher
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2009
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-3-7560

Other articles of this Issue 1/2009

Journal of Medical Case Reports 1/2009 Go to the issue